175 results about "Diabetic ulcers" patented technology

The present invention describes novel methods for using 9-deoxy-2′,9-α-methano-3-oxa-4,5,6-trinor-3,7-(1′,3′-interphenylene)-13,14-dihydro-prostaglandin F₁ (also known as Treprostinil) or its derivative, or a pharmaceutically acceptable salt thereof, for the treatment and/or prevention of foot ulcers in subjects with diabetic neuropathy. The invention also relates to kits for treatment and/or prevention of foot ulcers, comprising an effective amount of Treprostinil or its derivative, or a pharmaceutically acceptable salt thereof.

The wound assessing method and system provide a convenient, quantitative mechanism for diabetic foot ulcer assessment.

The present invention discloses an application of pentacyclic triterpenoid saponin represented by formulas (I) to (XIII) for the preparation of a medicine for preventing or treating AMPK-mediated diseases including fatty liver disease, inflammatory bowel disease, respiratory disease, diabetic complications and polycystic kidney disease. The compounds of formula (I) to (XIII) are especially usefulfor nonalcoholic simple fatty liver, nonalcoholic steatohepatitis, non-alcoholic steatohepatitis-induced cirrhosis, ulcerative colitis, Crohn's disease, chronic obstructive Pulmonary diseases, asthma,idiopathic pulmonary fibrosis, cystic fibrosis, allergic rhinitis, diabetic nephropathy, diabetic cardiomyopathy, diabetic ulcers, and autosomal dominant polycystic kidney disease. A pharmaceutical composition for preventing and treating the AMPK-mediated diseases of the present invention comprises a therapeutically effective amount of the compounds of the formula (I) to (XIII) or a pharmaceutically acceptable salt or a solvate thereof as an active ingredient and a pharmaceutically acceptable excipient.

Compositions and methods are provided for the treatment of chronic wounds, including, without limitation, pressure ulcers and diabetic ulcers, by transdermal delivery of an agent that increases activity of HIF-1α in the wound. Agents that increase HIF-1α activity include, without limitation, agents that stabilize HIF-1α, e.g. deferoxamine, deferiprone, deferasirox, etc.; agents that upregulate expression of HIF-1α, e.g. dimethyloxalylglycine, etc., HIF-1α polypeptide or coding sequences; and combinations thereof. Such agents may be referred to herein as HIF-1α potentiating agents.

The present disclosure provides apparatuses and methods for measuring capacitance as an indication of susceptibility to the formation of a diabetic foot ulcer.

Compositions and methods are provided for the prevention and treatment of chronic wounds, including, without limitation, pressure ulcers and diabetic ulcers, by transdermal delivery of an agent that increases activity of HIF-1α in the wound.

The present invention is related to a pharmaceutical composition comprising snail slime of Helix aspersa müller (Cryptophalus aspersus) (5% to 50%) and marigold extract, propolis and/or almond oil and pharmacologically accepted additives for the prevention additives and/or pharmaceutically acceptable excipients to form a formulation of intermediate to high viscosity (200 to 1000 Pa-s). This invention also relates to the use of a composition which can be formed as a cream or a gel, is preferably soaked in gauze, and shaped as a bandage or sock for the treatment and cure of diabetic foot ulcers and other severe wounds, particularly those associated with diabetes, gout, Lesch Nyhan syndrome or other conditions to the skin, including, keratosis, onychomycosis, ringworm, among others.

The invention provides an MG53 (mitsugumin53) mutant and a preparation method thereof. The mutant is a serine-site mutant of MG53 protein in a Coiled-coil structural domain, and the mutant results in inactivation of MG53 phosphorylation. Meanwhile, the MG53 protein mutant can be used for preventing or treating diseases related to cellular membrane damage, such as diseases related to myocardial cell injury, diseases related to ulcer, trauma with a wound, particularly a difficult-to-heal wound, intestinal leakage, kidney injury and the like. The diseases related to myocardial cell injury can include one or more diseases related to following symptoms: myocardial ischemia, heart ischemia, heart ischemia/reperfusion injury, myocardial infarction, cardiac failure, arrhythmia and cardiac rupture. The diseases related to ulcer include one or more of following diseases: chronic ulcer, peptic ulcer, diabetic foot ulcer, diabetic foot gangrene and chronic gastric ulcer. Besides, the invention further provides a dry powder preparation, a spray preparation, a gel preparation and an emulsion containing MG53 or MG53 mutant as well as preparation methods of the preparations.

A diabetic foot ulcer (DFU) classification method proposed in the invention based on a convolutional neural network includes the steps of creating a DFU data set, marking a region of interest (ROI), adding data, pre-processing training patches, conventional machine learning, and constructing a DFU network. The process includes: first collecting foot images of a DFU patient and a healthy person asdata sets and plotting ROIs, then adding data using a combination of various image processing techniques for network training, next, pre-processing the obtained patches, normalizing each pixel, and finally constructing a DFU network including input data, parallel convolutions, a fully connected layer, and an output classifier. The method of the invention utilizes an advanced convolutional neural network to process the input data more effectively and efficiently; and has high sensitivity and can effectively distinguish the characteristic differences between the healthy skin and the DFU, therebygreatly shortening the processing time.

The invention provides Chinese medicinal detoxifying myo-regeneration paste for treating diabetic foot ulcer, which belongs to the fields of traditional Chinese medical science and traditional Chinese medicines. The paste is prepared from the following raw materials in percentage by weight: 6 to 11 percent of rhubarb, 6 to 11 percent of golden thread, 6 to 11 percent of amur corktree bark, 14 to 19 percent of plaster, 12 to 17 percent of sinkiang arnebia root, 14 to 20 percent of Chinese angelica, 7 to 11 percent of angelica dahurica, 2 to 5 percent of calomel, 7 to 11 percent of dragon's blood and 23 to 30 percent of bee wax. Animal experiments and clinical researches prove that the Chinese medicinal detoxifying myo-regeneration paste provided by the invention has the effects of activating blood, dissolving stasis, removing putrefaction, regenerating myo, clearing away heat and toxic material and the like, has the advantages of keeping the surface of a wound wet, increasing the content of cell factors, namely, a vascular endothelial growth factor (VEGF) and a platelet-derived growth factor (PDGF) and promoting relevant gene expressions of muscles and blood vessels, along with definite curative effect, simple and convenient operation, economy, safety and no toxic or side effect and special significance in treating diabetic foot ulcer.

Compositions and methods are provided for the prevention and treatment of chronic wounds, including, without limitation, pressure ulcers and diabetic ulcers, by transdermal delivery of an agent that increases activity of HIF-1α in the wound.

The present invention provides methods and pharmaceutical formulations for treating diabetic foot ulcers.

The present invention provides methods and pharmaceutical formulations for treating diabetic foot ulcers.

The invention relates to a Chinese traditional medicine composition for treating stomatitis, which consists of the following Chinese herbal medicine materials in part by weight: 8 to 9 parts of honeysuckle flower, 8 to 12 parts of plaster stone, 4 parts of natural indigo, 4 parts of borneol, 3 to 9 parts of coptis root, 4 parts of frankincense and 3 to 7 parts of Chinese angelica. The invention can treat various forms of stomatitis, including ulcerous stomatitis, herpetic stomatitis, mycotic stomatitis, oral lichen planus and the like, and has a remarkable curative effect. In particular, the invention has the best curative effect on ulcerous stomatitis. Meanwhile, the Chinese traditional medicine composition also has a remarkable curative effect on body surface ulcers, bedsore, diabetic foot ulcers, erosion and wounds. The invention has the advantages of low cost, cheapness, safety, reliability, convenient use and remarkable effect, and is popular with patients.

The invention discloses a traditional Chinese medicine composition for external use for treating diabetic foot ulcer. The traditional Chinese medicine composition is prepared from the raw materials in parts by weight: coptis chinensis, pseudo-ginseng, lithospermum, salvia miltiorrhiza, golden cypress, frankincense, myrrh, dragon blood, beewax and calcined gypsum, wherein the raw materials have synergistic effects for recovering the elasticity for the blood vessels by clearing away heat and toxic materials and promoting blood circulation to remove blood stasis; the insufficient blood supply can trend to be normal in a slow process; gene regulation elements and effective active molecules in the traditional Chinese medicine raw materials can enter diseased parts of the blood; in a smooth and steady regulating process, the traditional Chinese medicine composition for external use can be used for repairing damaged tissues and organs of the body by improving liver and kidney mainly, controlling the diabetic pathogenesis step by step, regulating the human body nervous system and promoting blood circulation, playing a coordination and comprehensive treatment role, changing the diabetic pathogenesis radically and recovering the body; the traditional Chinese medicine composition for external use has the effects of removing slough and promoting growth of tissue regeneration, warming the meridians, tonifying qi and activating blood, alleviating phishom limb pain, controlling ulcer surface infection, improving local microcirculation, enhancing bidirectional transfer function of endothelial cells, improving conduction velocity of peripheral nerve and promoting the repair of the tissues and the healing of the wound surfaces.

Disclosed are methods, devices, and systems for treatment of an abnormal wound healing response. The methods, devices, and systems can be used to treat solid ulcerated tissue, such as diabetic foot ulcers (DFUs), arthritic tissue, muscle soreness, joint pain, varicose veins, obesity, and peripheral artery disease. Additionally, the methods, devices, and systems can promote the healing of xenograft, allograft, autograft, or engineered tissue following reconstruction surgery. The methods, devices, and systems include the ability to determine an optimal set of pulse parameters that are specific to wound healing. In embodiments, the methods, devices, and systems include components for guiding the user on electrode placement based on anatomical or electrical measurements, delivering a custom series of electric pulses, applying heat, and using feedback from physiologic measurements to control the device.